Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Timothy Wilens, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01270555
First received: January 3, 2011
Last updated: March 4, 2013
Last verified: March 2013
Results First Received: January 7, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Substance Use Disorder (SUD)
Intervention: Drug: Bupropion SR

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Bupropion Once daily treatment with Bupropion with intention to treat ADHD and SUD.

Participant Flow:   Overall Study
    Bupropion  
STARTED     32  
COMPLETED     19  
NOT COMPLETED     13  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Bupropion Once daily treatment with Bupropion with intention to treat ADHD and SUD.

Baseline Measures
    Bupropion  
Number of Participants  
[units: participants]
  32  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     32  
>=65 years     0  
Age  
[units: years]
Mean ± Standard Deviation
  32  ± 8.5  
Gender  
[units: participants]
 
Female     6  
Male     26  
Region of Enrollment  
[units: participants]
 
United States     32  
DSM-IV Attention Deficit Hyperactivity Rating Scale (ADHD RS) [1]
[units: Units on a scale]
Mean ± Standard Deviation
  34.1  ± 8.2  
Self-reported Weekly substance use [2]
[units: Participants]
  32  
Clinical Global Impressions (CGI) Score for SUD Severity [3]
[units: Units on a scale]
Mean ± Standard Deviation
  4.0  ± 0.9  
Clinical Global Impressions (CGI) Score for ADHD Severity [3]
[units: Units on a scale]
Mean ± Standard Deviation
  5.0  ± 0.7  
Hamilton Anxiety Rating Scale (HAM-A) [4]
[units: Units on a scale]
Mean ± Standard Deviation
  8.1  ± 6.5  
Hamilton Depression rating Scale (HAM-D) [5]
[units: Units on a scale]
Mean ± Standard Deviation
  8.8  ± 9.1  
Beck Depression Inventory (BDI) [6]
[units: Units on a scale]
Mean ± Standard Deviation
  8.9  ± 5.9  
[1] Assesses 18 individual criteria symptoms on a severity grid (0=not present, 3=severe; overall minimum score = 0, maximum score = 54)
[2] Participants who self-report using at least one of illegal drugs or alcohol, at least once per week.
[3] Global Severity 1=not ill, 7=extremely ill
[4] minimum (least severe anxiety) = 0, maximum (most severe) = 56
[5] minimum (least severe depression) = 0, maximum (most severe) = 84
[6] minimum (least severe depression) = 0, maximum (most severe) = 63



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) Score   [ Time Frame: baseline and six weeks ]

2.  Primary:   Self-reported Weekly Substance Use   [ Time Frame: baseline and six weeks ]

3.  Secondary:   Clinical Global Impressions (CGI) Scale of Substance Use Disorder (SUD) Severity   [ Time Frame: baseline and six weeks ]

4.  Secondary:   Clinical Global Impressions (CGI) Scale of ADHD Severity   [ Time Frame: baseline and six weeks ]

5.  Secondary:   Hamilton Anxiety Scale (HAM-A)   [ Time Frame: baseline and six weeks ]

6.  Secondary:   Hamilton Depression Scale (HAM-D)   [ Time Frame: baseline and six weeks ]

7.  Secondary:   Beck Depression Inventory (BDI)   [ Time Frame: baseline and six weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Timothy Wilens, MD
Organization: Massachusetts General Hospital
phone: 617-503-1053
e-mail: twilens@partners.org


No publications provided


Responsible Party: Timothy Wilens, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01270555     History of Changes
Obsolete Identifiers: NCT01012024
Other Study ID Numbers: 1999-P-009198
Study First Received: January 3, 2011
Results First Received: January 7, 2011
Last Updated: March 4, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board